Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

Molecular Partners Showcases Bispecific Radio-DARPins at --> Accessibility: Skip TopNav Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference July 15, 2026 01:00 ET | Source: Molecular Partners Molecular Partners Developing bispecific Radio-DARPins to engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy Presentation outlines Radio-DARPins’ ability to match target and disease biology for improved outcomes ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today highlights its approaches to overcoming target limitations in radioligand therapy (RLT) through Radio-DARPins, in a presentation at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer in Newry, Maine, US. Title: Appropriate Targets for RLT? High selectivity vs high expression Presenter: Daniel Steiner, Ph.D. Time: Wednesday July 15 at 11:10-11:30 ET The presentation outlines the ability of DARPins to match the biological characteristics of both the target and the disease, by optimizing their binding properties, systemic half-life, and biodistribution. To address tumor heterogeneity, Molecular Partners is also developing multispecific Radio-DARPins that can engage multiple tumor targets simultaneously, improving precision and therapeutic efficacy. "Our multispecific Radio-DARPin approaches reflect Molecular Partners’ ambition to push the boundaries of radiotheranostics and address the complexity and heterogeneity of cancer. By combining the versatility of DARPins with our deep expertise in designing multispecific medicines, we are exploring innovative approaches that have the potential to broaden patient reach and improve outcomes. This work represents an important step toward the next generation of radiopharmaceuticals," said Daniel Steiner, Ph.D., SVP of Targeted Radio Therapeutics at Molecular Partners. Building on the success of its first “mono”-targeting Radio-DARPins, the Company is highlighting the ability to expand its impact in the field of RLT through multispecific DARPins. These can be formatted either as a bispecific (two DARPins each binding an individual target) or as a 2-in-1 DuoDARPin (one DARPin able to bind two tumor targets in an either/or manner). The Company’s multispecific approaches enable the design of radiopharmaceuticals for effective treatment of highly heterogenous cancers, with target expression variability across tumor lesions and patients. Such bispecific radiopharmaceuticals could allow to treat cancer indications in which two targets are co-expressed solely on tumor tissues, creating tumor-specific solutions for patients with limited therapeutic options today. Molecular Partners’ lead Radio-DARPin candidate MP0712, co-developed with Orano Med and targeting delta-like ligand 3 (DLL3), is in a multicenter US Phase 1/2a trial, building on the successful generation of first imaging and dosimetry data from a compassionate care program. The second candidate MP0726, targeting mesothelin MSLN, is differentiated by its ability to selectively bind membrane-bound MSLN, and work towards first human imaging is expected this year. Molecular Partners expects to announce a third Radio-DARPin program, targeting a different tumor target, in 2026. Following today’s presentation, a copy of the presentation from the Gordon Research Conference will be available on Molecular Partners website, under Scientific Documents . About Gordon Research Conferences Founded in 1931, Gordon Research Conferences (GRC) is a nonprofit organization based in Rhode Island that organizes a series of internationally recognized scientific conferences across the biological, chemical, and physical sciences. GRC hosts hundreds of conferences annually, spanning fields from physics and neurobiology to materials science and medicine, and its meetings are known for fostering in-depth scientific discussion among leading researchers in each field. Attendance is limited and application-based, with participants selected by the conference chair, encouraging close interaction and community-building among scientists advancing the frontier of their fields. About Radio-DARPins Molecular Partners develops targeted alpha therapeutics leveraging its Radio-DARPins as isotope-agnostic vectors with the potential to unlock a broad range of cancer targets and indications. Molecular Partners designs its Radio-DARPin candidates matching disease and target biology with vector and isotope properties to address unmet medical needs. Building on the DARPins’ unique properties, Molecular Partners has developed a proprietary Radio-DARPin platform for precise delivery of potent radioactive payloads to tumor lesions. Molecular Partners’ Radio-DARPins address hist